VPRIV®

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
19	ライソゾーム病	2

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02574286 (ClinicalTrials.gov)	June 29, 2016	9/10/2015	Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Part ...	An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase ...	Gaucher Disease	Drug: Velaglucerase alfa;Dietary Supplement: Vitamin D	Shire	NULL	Completed	18 Years	70 Years	All	21	Phase 4	United States;Israel;Spain;United Kingdom
2	NCT00635427 (ClinicalTrials.gov)	May 2008	6/3/2008	An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease	An Open-Label Extension Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacemen ...	Gaucher Disease, Type 1	Biological: VPRIV®	Shire	NULL	Completed	2 Years	N/A	All	95	Phase 3	United States;Argentina;India;Israel;Korea, Republic of;Paraguay;Poland;Russian Federation;Spain;Tun ...

First Previous1Next Last